NCT06982924View on ClinicalTrials.gov

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions
EGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive
Interventions
DRUG

Limertinib+bevacizumab

The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive the combination of Limertinib with bevacizuma in first-line treatment

DRUG

Limertinib

The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive Limertinib in first-line treatment

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Shanghai Chest Hospital

OTHER

NCT06982924 - A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. | Biotech Hunter | Biotech Hunter